Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 25.9% in December

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 26,900 shares, a drop of 25.9% from the November 30th total of 36,300 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 119,300 shares, the days-to-cover ratio is presently 0.2 days.

Xtant Medical Trading Up 6.9 %

NYSEAMERICAN XTNT traded up $0.03 during trading hours on Friday, hitting $0.46. The company’s stock had a trading volume of 75,904 shares, compared to its average volume of 113,672. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. Xtant Medical has a twelve month low of $0.33 and a twelve month high of $1.31. The firm has a market capitalization of $64.51 million, a P/E ratio of -3.57 and a beta of 0.34.

Xtant Medical (NYSEAMERICAN:XTNT) last posted its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The business had revenue of $27.94 million for the quarter.

Institutional Investors Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Geode Capital Management LLC raised its holdings in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 515,006 shares of the medical device company’s stock after acquiring an additional 212,394 shares during the period. Geode Capital Management LLC owned about 0.37% of Xtant Medical worth $348,000 at the end of the most recent quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the company a “buy” rating in a research note on Friday, October 18th.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.